Portfolio
& Pipeline
We have developed a proven portfolio of advanced medical devices already trusted in clinical settings, with additional innovations actively progressing through our development pipeline. Our commitment to next-generation wound care, infection control, and skin protection drives a continual evolution of science-backed solutions that improve patient outcomes.
Drug Candidates
Drug Candidate
For the Treatment of
Moderate to Severe Eczema
Turn Therapeutics’ flagship formula has been confirmed to inhibit the immune signals that lead to eczema, known as cytokines, specifically IL36a, IL36y, Il4, and IL31. This same formula has been FDA cleared for additional indications in which it was confirmed non-cytotoxic and non-sensitizing.
Drug Candidate
For the Treatment of
Onychomycosis
Topical antifungals are widely considered ineffective per CDC (6-16%), yet still generate billions of dollars in revenue annually.
Preliminary research conducted by key opinion leading physicians suggests our flagship formula’s potential efficacy is ~70-85% (n=100) for the treatment of onychomycosis.
Drug Candidate
Indicated for
MRSA-Pathogen Burden Reduction
Nasal decolonization is a common part of protocols intended to reduce the likelihood of systemic infections caused by MRSA.
Our formulation is 99.9% effective against MRSA, biocompatible, and meets eligibility requirements for FDA’s QIDP program.
Medical Devices
Our portfolio of FDA cleared medical devices have over 200,000 human uses and zero reported adverse events.
Medical Device
Antimicrobial Oil Emulsion Dressing
XEAL
XEAL Antimicrobial Oil Emulsion Dressing is impregnated with petrolatum-based Hexagen Antimicrobial.
Medical Device
Antimicrobial Collagen Powder
FLEX AM
Medical Device
Management of Atopic Dermatitis
AtopX
The same formula composition as our original, flagship Hexagen formula indicated for the management of symptoms related to atopic, irritant, and radiation dermatitis.
Lead candidate for drug approval for the treatment of moderate to severe eczema. Drug approval will facilitate patient access through traditional retail pharmacy channels.
